Cynosure Fund Company Profile

Description

Cynosure, Inc. develops, manufactures, and markets aesthetic treatment systems for plastic surgeons, dermatologists, and other medical practitioners. The company’s aesthetic treatment systems utilize a range of energy sources, including Alexandrite, diode, Nd: YAG, pulse dye, Q-switched lasers, intense pulsed light, and radiofrequency (RF) technology. It offers Elite product line for hair removal, and treatment of facial and leg veins and pigmentations; SmartLipo product line for LaserBodySculpting for the removal of unwanted fat; Cellulaze product line for the treatment of cellulite; Cynergy product line for the treatment of vascular lesions; MedLite C6 and RevLite product lines for the removal of benign pigmented lesions, as well as multi-colored tattoos; and PicoSure product line for the treatment of tattoos, benign pigmented lesions, acne scars, fine lines, and wrinkles. The company also provides Icon aesthetic system for hair removal, wrinkle reduction, and scar and stretch mark treatment; Vectus diode laser for high volume hair removal; SculpSure hyperthermic laser treatment for LaserBodySculpting for non-invasive fat reduction; and MonaLisa Touch laser for gynecologic health. In addition, it markets radiofrequency energy sourced medical devices for precision surgical applications, such as facial plastic and general surgery, gynecology, ear, nose, and throat procedures, ophthalmology, oral and maxillofacial surgery, podiatry, and proctology. The company sells its products through a direct sales force in the United States, Canada, France, Morocco, Germany, Spain, the United Kingdom, Australia, China, Japan, and South Korea, as well as through independent distributors in approximately 120 countries. Cynosure, Inc. was founded in 1991 and is headquartered in Westford, Massachusetts.